A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.
JACC Basic Transl Sci
; 7(8): 763-775, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-36061336
AE, adverse event; AUC24, area under the plasma concentrationtime curve from time 0 to 24 hours; CV%,, percent coefficient of variation; CYP, cytochrome P450; CYP2D6-PM, cytochrome P450 2D6 poor metabolizer phenotype; Cmax, maximum plasma drug concentration; DLRC, Dose Level Review Committee; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; LV contractility; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MAD, multiple ascending dose; PD, pharmacodynamic; PK, pharmacokinetic; QTcF, QT interval corrected for heart rate using Fridericia's formula; SAD, single ascending dose; TEAE, treatment-emergent adverse event; aficamten; cardiac myosin inhibitor; hypertrophic cardiomyopathy; phase 1
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
JACC Basic Transl Sci
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos